Developer docs
API playgroundTry for free, no card

Search company profiles

Pheno therapeutics

Full company profile

uuid000ivye

Namestring
Pheno therapeutics
Legal namestring
Pheno Therapeutics Limited
Company typeenum
Private
Founded yearint
2017
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEdinburgh, United Kingdom
HQ citystring
Edinburgh
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
remyelination therapeutics, multiple sclerosis drugs, small molecule discovery, oligodendrocyte biology, neurodegenerative disease treatment
Industry3 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Multiple Sclerosis Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Pharmaceutical Development and Commercialization
TypeLicensing Royalties
Description

As a clinical-stage biotechnology company, Pheno Therapeutics is developing small molecule therapeutics for the treatment of neurological diseases. The company plans to commercialize its pipeline through eventual pharmaceutical partnerships or direct commercialization. Revenue will be derived from licensing deals, milestone payments, androyalties on net sales from developed therapeutics.

phenotherapeutics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Pheno Therapeutics is a clinical-stage biotech developing small molecule GPR17 antagonists designed to promote remyelination in neurological diseases, with lead candidate PTD802 advancing through first-in-human trials for multiple sclerosis. The company leverages a proprietary human phenotypic screening platform to discover targets that modulate oligodendrocyte biology, developing therapeutics under an exclusive worldwide license from UCB. Its pipeline addresses demyelinating disorders including MS, Alzheimer's disease, ALS, Parkinson's disease, and rare leukodystrophies.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • GPR17 receptor blockade enables promotion of remyelination in neurological diseases
+1 more record
Product overview1 text field

Pheno Therapeutics is a clinical stage biotech company developing a portfolio of small molecule GPR17 antagonists for neurodegenerative and demyelinating disorders. The lead product is PTD802, a selective GPR17 antagonist designed to promote remyelination for multiple sclerosis treatment. The company operates a GPR17 antagonist discovery platform that leverages proprietary human phenotypic screening to identify novel molecules that boost oligodendrocyte function and natural remyelination capacity.

Product and service2 records
1PTD802
CategoryMultiple Sclerosis Therapeutics
Description

PTD802 is a selective GPR17 antagonist and novel small molecule therapeutic candidate designed to promote remyelination in neurological diseases, with initial focus on multiple sclerosis. It is the first GPR17 programme to receive FDA IND clearance globally and is being advanced under an exclusive worldwide license from UCB into first-in-human clinical trials.

2GPR17 Antagonist Discovery Platform
CategoryDrug Discovery Platform
Description

A proprietary human phenotypic screening and drug discovery platform that harnesses GPR17 biology to identify small molecules that boost oligodendrocyte function and unlock the brain's endogenous remyelination capacity, serving as the engine for Pheno Therapeutics' GPR17 antagonist pipeline.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership3 partners
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2023-01-11
Description

Pheno Therapeutics entered into an exclusive worldwide license agreement with UCB in January 2023. The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination. The license covers the GPR17 program including PTD802. UCB receives milestones and tiered royalties on net sales.

2University of Edinburgh
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-01-11
Description

Original research by Professors Siddharthan Chandran and Neil Carragher of the University of Edinburgh formed the basis for Pheno Therapeutics. The company combines world leading expertise in myelin biology, MS trials, patient selection and clinical cohorts from academic founders.

phenotherapeutics.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-02-20
Description

The University's commercialisation service that helped bring together the scientific and clinical expertise in partnership with Advent Life Sciences to launch the company. Supported the formation of Pheno Therapeutics by facilitating partnership between academic founders and venture capital.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage company developing CNM-Au8, a gold nanocatalyst designed to promote remyelination and neuroprotection in MS and other neurological diseases — directly comparable mechanism and indication focus.

TypeDirect peer
Description

Clinical-stage biotech developing remyelination and neuroprotective therapies for MS and other CNS disorders; competes in the same disease-modifying remyelination space as PTD802.

TypeDirect peer
Description

Clinical-stage company developing ibudilast (MN-166) for progressive MS and other neurological conditions; a peer in MS drug development with CNS anti-inflammatory/neuroprotective focus.

TypeBroad incumbent
Description

Global MS market leader with Tysabri, Avonex, and Plegridy; defines the standard of care Pheno's remyelination approach would need to improve upon, and is a natural acquirer/partner for late-stage CNS assets.

TypeBroad incumbent
Description

Holds major MS franchise assets (Gilenya, Kesimpta) and is the largest pharma in neuroscience; a relevant comparator as a potential commercial partner or acquirer for remyelination therapies.

TypeEmerging player
Description

Clinical-stage biotech developing immuno-neurology therapies for neurodegenerative diseases (Alzheimer's, FTD); relevant emerging peer in the broader CNS neurodegeneration space Pheno's pipeline targets.

TypeEmerging player
Description

Clinical-stage biotech developing small molecules (e.g., blarcamesine) targeting CNS indications including MS and neurodegenerative diseases; an emerging player in the same therapeutic space.

TypeOthers
Description

AI-driven CNS drug discovery company; linked via Chair Jane Rhodes (former President & CBO) and represents the broader neurodegenerative drug discovery ecosystem that Pheno Therapeutics operates within.

TypeOthers
Description

CNS-focused biotech (now part of BMS) that developed xanomeline for CNS indications; serves as a relevant precedent for clinical-stage CNS biotechs achieving major pharma exits and validates the commercial attractiveness of CNS assets.

TypeBroad incumbent
Description

Owns Ocrevus, the leading high-efficacy MS therapy, and has CNS R&D investments; comparable as the dominant benchmark in MS therapeutics.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pheno therapeutics

Multiple Sclerosis Therapeuticsphenotherapeutics.com

Pheno therapeutics firmographics

Firmographics
Name
Pheno therapeutics
Legal name
Pheno Therapeutics Limited
Website
https://phenotherapeutics.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
1–10 employees
Ownership category
akta.pro rank

Pheno therapeutics industry classification

Industry
Product category
Multiple Sclerosis Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAIAD
Rare Neurology & Neurodegenerative Disorder Therapies
Healthcare & Life Sciences/Pharmaceuticals/Orphan & Rare Disease Pharmaceuticals
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Remyelination therapeutics
  • Multiple sclerosis drugs
  • Small molecule discovery
  • Oligodendrocyte biology
  • Neurodegenerative disease treatment

Where Pheno therapeutics is headquartered

Location

Headquarters

HQ city
Edinburgh
HQ country
United Kingdom
HQ region
Europe

Offices1 record

Markets served

Pheno therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Pharmaceutical Development and Commercialization: As a clinical-stage biotechnology company, Pheno Therapeutics is developing small molecule therapeutics for the treatment of neurological diseases. The company plans to commercialize its pipeline through eventual pharmaceutical partnerships or direct commercialization. Revenue will be derived from licensing deals, milestone payments, androyalties on net sales from developed therapeutics.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Pheno therapeutics product offering

Product offering

Core offering

Pheno Therapeutics is a clinical-stage biotech developing small molecule GPR17 antagonists designed to promote remyelination in neurological diseases, with lead candidate PTD802 advancing through first-in-human trials for multiple sclerosis. The company leverages a proprietary human phenotypic screening platform to discover targets that modulate oligodendrocyte biology, developing therapeutics under an exclusive worldwide license from UCB. Its pipeline addresses demyelinating disorders including MS, Alzheimer's disease, ALS, Parkinson's disease, and rare leukodystrophies.

Product overview

Pheno Therapeutics is a clinical stage biotech company developing a portfolio of small molecule GPR17 antagonists for neurodegenerative and demyelinating disorders. The lead product is PTD802, a selective GPR17 antagonist designed to promote remyelination for multiple sclerosis treatment. The company operates a GPR17 antagonist discovery platform that leverages proprietary human phenotypic screening to identify novel molecules that boost oligodendrocyte function and natural remyelination capacity.

Differentiator

Problem solved

Functional benefit

Products and services

  • PTD802 PTD802 is a selective GPR17 antagonist and novel small molecule therapeutic candidate designed to promote remyelination in neurological diseases, with initial focus on multiple sclerosis. It is the first GPR17 programme to receive FDA IND clearance globally and is being advanced under an exclusive worldwide license from UCB into first-in-human clinical trials.
  • GPR17 Antagonist Discovery Platform A proprietary human phenotypic screening and drug discovery platform that harnesses GPR17 biology to identify small molecules that boost oligodendrocyte function and unlock the brain's endogenous remyelination capacity, serving as the engine for Pheno Therapeutics' GPR17 antagonist pipeline.

Quantifiable outcome

  • GPR17 receptor blockade enables promotion of remyelination in neurological diseases
  • +1 more outcomes

Companies that use Pheno therapeutics

Customer profile

Segments2 records

Ideal customer profiles2 records

Pheno therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Pheno therapeutics partnerships and signals

Strategic signal

Partnerships

Three partnerships are on record, tiered core.

  • UCBcoreOEM/ Whitelabel/ Licensing Partner · 11 January 2023Pheno Therapeutics entered into an exclusive worldwide license agreement with UCB in January 2023. The agreement grants Pheno Therapeutics access and rights to develop, manufacture and commercialize a preclinical-stage program of novel small molecules designed to promote remyelination. The license covers the GPR17 program including PTD802. UCB receives milestones and tiered royalties on net sales.
  • University of EdinburghcoreStrategic or Co-development Partner · 11 January 2023Original research by Professors Siddharthan Chandran and Neil Carragher of the University of Edinburgh formed the basis for Pheno Therapeutics. The company combines world leading expertise in myelin biology, MS trials, patient selection and clinical cohorts from academic founders.
  • Edinburgh InnovationscoreStrategic or Co-development Partner · 20 February 2020The University's commercialisation service that helped bring together the scientific and clinical expertise in partnership with Advent Life Sciences to launch the company. Supported the formation of Pheno Therapeutics by facilitating partnership between academic founders and venture capital.

Scale indicators4 records

Recent moves6 records

Expansion highlights5 records

Pheno therapeutics competitors and assessment

Company assessment

Direct peers

  • Clene Nanomedicine: Clinical-stage company developing CNM-Au8, a gold nanocatalyst designed to promote remyelination and neuroprotection in MS and other neurological diseases — directly comparable mechanism and indication focus.
  • Pipeline Therapeutics: Clinical-stage biotech developing remyelination and neuroprotective therapies for MS and other CNS disorders; competes in the same disease-modifying remyelination space as PTD802.
  • MediciNova: Clinical-stage company developing ibudilast (MN-166) for progressive MS and other neurological conditions; a peer in MS drug development with CNS anti-inflammatory/neuroprotective focus.

Broad incumbents

  • Biogen: Global MS market leader with Tysabri, Avonex, and Plegridy; defines the standard of care Pheno's remyelination approach would need to improve upon, and is a natural acquirer/partner for late-stage CNS assets.
  • Novartis: Holds major MS franchise assets (Gilenya, Kesimpta) and is the largest pharma in neuroscience; a relevant comparator as a potential commercial partner or acquirer for remyelination therapies.
  • Roche: Owns Ocrevus, the leading high-efficacy MS therapy, and has CNS R&D investments; comparable as the dominant benchmark in MS therapeutics.

Emerging players

  • Alector: Clinical-stage biotech developing immuno-neurology therapies for neurodegenerative diseases (Alzheimer's, FTD); relevant emerging peer in the broader CNS neurodegeneration space Pheno's pipeline targets.
  • Anavex Life Sciences: Clinical-stage biotech developing small molecules (e.g., blarcamesine) targeting CNS indications including MS and neurodegenerative diseases; an emerging player in the same therapeutic space.

Others

  • Verge Genomics: AI-driven CNS drug discovery company; linked via Chair Jane Rhodes (former President & CBO) and represents the broader neurodegenerative drug discovery ecosystem that Pheno Therapeutics operates within.
  • Karuna Therapeutics: CNS-focused biotech (now part of BMS) that developed xanomeline for CNS indications; serves as a relevant precedent for clinical-stage CNS biotechs achieving major pharma exits and validates the commercial attractiveness of CNS assets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pheno therapeutics social profiles

Digital presence

Pheno therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pheno therapeutics leadership team

Management profile

Number of profiles

Profiles7 records

Pheno therapeutics funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pheno therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pheno therapeutics

What does Pheno therapeutics do?

Pheno Therapeutics is a clinical-stage biotech developing small molecule GPR17 antagonists designed to promote remyelination in neurological diseases, with lead candidate PTD802 advancing through first-in-human trials for multiple sclerosis. The company leverages a proprietary human phenotypic screening platform to discover targets that modulate oligodendrocyte biology, developing therapeutics under an exclusive worldwide license from UCB. Its pipeline addresses demyelinating disorders including MS, Alzheimer's disease, ALS, Parkinson's disease, and rare leukodystrophies.

Is Pheno therapeutics a public or private company?

Pheno therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pheno therapeutics founded?

Pheno therapeutics was founded in 2017. It employs 1 to 10 people.

Where is Pheno therapeutics based?

Pheno therapeutics is headquartered in Edinburgh, United Kingdom, in the Europe region.

How does Pheno therapeutics make money?

One revenue line is on record: pharmaceutical Development and Commercialization.

Who are Pheno therapeutics's main competitors?

Direct peers on record are Clene Nanomedicine, Pipeline Therapeutics and MediciNova. Broad incumbents are Biogen, Novartis and Roche. Emerging players are Alector and Anavex Life Sciences. Others are Verge Genomics and Karuna Therapeutics.

Does Pheno therapeutics have an API?

No public API is recorded for Pheno therapeutics.

What industry is Pheno therapeutics in?

Pheno therapeutics's product category is Multiple Sclerosis Therapeutics. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals